The MicroRNA Expression Changes Associated with Malignancy and SDHB Mutation in Pheochromocytoma

Overview

Journal Endocr Relat Cancer

Specialties Endocrinology
Oncology

Date 2012 Jan 14

PMID 22241719

Citations 36

Authors

E Patterson

R Webb

A Weisbrod

B Bian

M He

L Zhang

A K Holloway

R Krishna

N Nilubol

K Pacak

E Kebebew

Affiliations

Soon will be listed here.

Abstract

Currently, the diagnosis of malignant pheochromocytoma can only be made when there is clinical evidence of metastasis or extensive local invasion. Thus, there is a need for new diagnostic marker(s) to identify tumors with malignant potential. The purpose of this study was to identify microRNAs (miRNAs) that are differentially expressed between benign and malignant pheochromocytomas and assess their diagnostic accuracy. Toward this aim, we analyzed miRNA expression in benign and malignant pheochromocytoma tumor samples using whole genome microarray profiling. Microarray analysis identified eight miRNAs that were significantly differentially expressed between benign and malignant pheochromocytomas. We measured a subset of these miRNAs directly by RT-PCR and found that miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts. Area under the receiver operating curve (AUC) analysis indicated that miR-483-5p, miR-101, and miR-183 could be useful diagnostic markers for distinguishing malignant from benign pheochromocytomas. In addition, these miRNAs could be detected in pheochromocytoma patient serum. Overall our data suggest that misexpression of miR-483-5p, miR-101, and miR-183 is associated with malignant pheochromocytoma.

Citing Articles

Circulating non-coding RNA biomarkers of endocrine tumours.

Butz H, Patocs A, Igaz P Nat Rev Endocrinol. 2024; 20(10):600-614.

PMID: 38886617 DOI: 10.1038/s41574-024-01005-8.

From diagnosis to resistance: a symphony of miRNAs in pheochromocytoma progression and treatment response.

Elsakka E, ElShafei A, Elkady M, Yehia A, Abulsoud A, Shahin R Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(4):1957-1969.

PMID: 37801146 DOI: 10.1007/s00210-023-02759-0.

Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options.

Eid M, Foukal J, Sochorova D, Tucek S, Stary K, Kala Z Cancer Med. 2023; 12(13):13942-13957.

PMID: 37145019 PMC: 10358258. DOI: 10.1002/cam4.6010.

Overexpression of miR-375 and L-type Amino Acid Transporter 1 in Pheochromocytoma and Their Molecular and Functional Implications.

Manso J, Bertazza L, Barollo S, Mondin A, Censi S, Carducci S Int J Mol Sci. 2022; 23(5).

PMID: 35269556 PMC: 8910416. DOI: 10.3390/ijms23052413.

The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update.

Bouca B, Bogalho P, Rizzo M, Silva-Nunes J Metabolites. 2022; 12(2).

PMID: 35208206 PMC: 8880811. DOI: 10.3390/metabo12020131.

References

Comino-Mendez I, Gracia-Aznarez F, Schiavi F, Landa I, Leandro-Garcia L, Leton R . Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011; 43(7):663-7. DOI: 10.1038/ng.861. View

Plouin P, Amar L, Lepoutre C . Phaeochromocytomas and functional paragangliomas: clinical management. Best Pract Res Clin Endocrinol Metab. 2010; 24(6):933-41. DOI: 10.1016/j.beem.2010.10.002. View

Smyth G, Michaud J, Scott H . Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005; 21(9):2067-75. DOI: 10.1093/bioinformatics/bti270. View

Tombol Z, Eder K, Kovacs A, Szabo P, Kulka J, Liko I . MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol. 2010; 23(12):1583-95. DOI: 10.1038/modpathol.2010.164. View

Gimenez-Roqueplo A, Favier J, Rustin P, Rieubland C, Crespin M, Nau V . Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003; 63(17):5615-21. View

Sarver A, Li L, Subramanian S . MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 2010; 70(23):9570-80. DOI: 10.1158/0008-5472.CAN-10-2074. View

Grogan R, Mitmaker E, Duh Q . Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control. 2011; 18(2):104-12. DOI: 10.1177/107327481101800205. View

Ozata D, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A . The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer. 2011; 18(6):643-55. PMC: 3201061. DOI: 10.1530/ERC-11-0082. View

Neumann H, Sullivan M, Winter A, Malinoc A, Hoffmann M, Boedeker C . Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab. 2011; 96(8):E1279-82. DOI: 10.1210/jc.2011-0114. View

10.

Zarnegar R, Kebebew E, Duh Q, Clark O . Malignant pheochromocytoma. Surg Oncol Clin N Am. 2006; 15(3):555-71. DOI: 10.1016/j.soc.2006.05.009. View

11.

Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J . Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007; 92(10):3822-8. DOI: 10.1210/jc.2007-0709. View

12.

Smyth G . Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2006; 3:Article3. DOI: 10.2202/1544-6115.1027. View

13.

Mitchell P, Parkin R, Kroh E, Fritz B, Wyman S, Pogosova-Agadjanyan E . Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513-8. PMC: 2492472. DOI: 10.1073/pnas.0804549105. View

14.

Hannafon B, Sebastiani P, de las Morenas A, Lu J, Rosenberg C . Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res. 2011; 13(2):R24. PMC: 3219184. DOI: 10.1186/bcr2839. View

15.

Benn D, Gimenez-Roqueplo A, Reilly J, Bertherat J, Burgess J, Byth K . Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2005; 91(3):827-36. DOI: 10.1210/jc.2005-1862. View

16.

Yang Y, Dudoit S, Luu P, Lin D, Peng V, Ngai J . Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002; 30(4):e15. PMC: 100354. DOI: 10.1093/nar/30.4.e15. View

17.

Meyer-Rochow G, Jackson N, Conaglen J, Whittle D, Kunnimalaiyaan M, Chen H . MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer. 2010; 17(3):835-46. DOI: 10.1677/ERC-10-0142. View

18.

Ferracin M, Veronese A, Negrini M . Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010; 10(3):297-308. DOI: 10.1586/erm.10.11. View

19.

Patterson E, Holloway A, Weng J, Fojo T, Kebebew E . MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer. 2011; 117(8):1630-9. PMC: 3051015. DOI: 10.1002/cncr.25724. View

20.

Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Perez L, King E . Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010; 304(23):2611-9. DOI: 10.1001/jama.2010.1830. View